De-identified data fuels AI-driven drug differentiation

De-identified data fuels AI-driven drug differentiation

Client Context

  • Global pharma company consolidating large volumes of patient data into a diverse data platform.
  • The goal is to improve drug development by unleashing the power of artificial intelligence.

Business Challenge

  • Unlocking the value of clinical study data for internal use with highly automated de-identification.

Privacy Analytics Solution

  • Using Eclipse, the company will de-identify thousands of clinical studies, achieving high-utility data that is compliant with global privacy regulations.
  • Eclipse enterprise-class anonymization software provides auditable proof that the company is taking legally defensible steps to protect the privacy of clinical trial participants.
  • In addition to trial-specific features for real world evidence, Eclipse provides capability to anonymize other data types (e.g. DICOM headers) and measure the risk of re-identification for various disclosure contexts (e.g. external researchers).

Business Impact

  • The company is now well positioned to transform life sciences and change the way medicines are developed.
  • Competitive advantage by leveraging best-of-breed anonymization software that is proven across diverse tech environments globally.

Discover our Eclipse Trials software and how it can help your business.

More Case Studies

Previous
Next

Join the next 5 Safes Data Privacy webinar

This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.